Ipsen Shares Drop 2% and Fall Below Short-Term Moving Averages
The French biopharmaceutical company is down in early afternoon trading in a declining Parisian market. The stock is erasing some of its recent rebound as technical indicators continue to deteriorate in the short term.
A Decline That Brings the Stock Below its 20 and 50-Day Moving Averages
Ipsen shares are down 2.09% at €154.60, following a previous close at €157.90. The stock is part of a CAC 40 that is down by 0.6% and an SBF 120 that has lost 0.63%.
The movement brings the price below the MM20 (€158.39, a gap of -2.39%) and the MM50 (€161.89, a gap of -4.50%). The MM200 at €137.97 remains 12% below the current price, which keeps the underlying bullish trend intact (+48.65% over one year).
The RSI at 48 is in a neutral zone and does not send an extreme signal. The support threshold at €151.30 is the next technical area nearby, about 2% from the current price.
An Active Clinical Pipeline Following Several Anticipated Phase III Readings
The laboratory continues to engage in scientific meetings. At the end of May, Iqirvo confirmed its effectiveness on fatigue and alkaline phosphatases at the EASL congress for primary biliary cholangitis.
During the results announcement on May 28, 2026, the company highlighted significant improvements in 67% of patients treated with Iqirvo, while also noting the competition from generics and regulatory uncertainties as major risks.
There has also been recent movement in governance, with Karen Witts departing from the board after the general meeting on May 13 and Pascal Touchon serving as interim on the audit committee. Despite a decline of 7.09% over the last month, the stock still maintains a gain of 48.65% over the past year.
